Up big on Phase 2a reports for their IPF drug.
They also have a NASH drug in Phase 2
$700 million market cap for a potential blockbuster drug.
Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced positive data from INTEGRIS-IPF, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF). The trial met its primary and secondary endpoints demonstrating that PLN-74809 was well tolerated over a 12-week treatment period and displayed a favorable pharmacokinetic profile.
90 patients, well tolerated on all doses.